Kumar Bhupinder, Thakur Amandeep, Dwivedi Ashish Ranjan, Kumar Rakesh, Kumar Vinod
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, 151001, India.
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab, 142001, India.
Curr Med Chem. 2022;29(10):1757-1803. doi: 10.2174/0929867328666210512005508.
Alzheimer's disease (AD) is a complex neurological disorder and multiple pathological factors are believed to be involved in the genesis and progression of the disease. A number of hypothesis including Acetylcholinesterase, Monoamine oxidase, β- Amyloid, Tau protein etc. have been proposed for the initiation and progression of the disease. At present, acetylcholine esterase inhibitors and memantine (NMDAR antagonist) are the only approved therapy for the symptomatic management of AD. Most of these single-target drugs have miserably failed in the treatment or halting the progression of the disease. Multi-factorial diseases like AD require complex treatment strategies that involve simultaneous modulation of a network of interacting targets. Since last few years, Multi-Target-Directed Ligands (MTDLs) strategy, drugs that can simultaneously hit multiple targets, is being explored as an effective therapeutic approach for the treatment of AD. In the current review article, the authors have briefly described various pathogenic pathways associated with the AD. Importance of Multi-Target-Directed Ligands and their design strategies in recently reported articles have been discussed in detail. Potent leads identified through various structure-activity relationship studies and their drug like characteristics are described. Recently developed promising compounds have been summarized in the article. Some of these MTDLs with balanced activity profile against different targets have the potential to be developed as drug candidates for the treatment of AD.
阿尔茨海默病(AD)是一种复杂的神经疾病,多种病理因素被认为与该疾病的发生和发展有关。针对该疾病的起始和进展,已经提出了许多假说,包括乙酰胆碱酯酶、单胺氧化酶、β-淀粉样蛋白、 Tau蛋白等。目前,乙酰胆碱酯酶抑制剂和美金刚(NMDAR拮抗剂)是唯一被批准用于AD症状管理的治疗方法。这些单一靶点药物大多在治疗或阻止疾病进展方面惨遭失败。像AD这样的多因素疾病需要复杂的治疗策略,包括同时调节相互作用靶点网络。在过去几年中,多靶点导向配体(MTDLs)策略,即能够同时作用于多个靶点的药物,正被探索作为治疗AD的一种有效治疗方法。在当前的综述文章中,作者简要描述了与AD相关的各种致病途径。详细讨论了多靶点导向配体的重要性及其在最近报道文章中的设计策略。描述了通过各种构效关系研究确定的有效先导化合物及其类药特性。文章总结了最近开发的有前景的化合物。其中一些对不同靶点具有平衡活性的MTDLs有潜力被开发为治疗AD的候选药物。